Latest news with #animalhealth
Yahoo
21-07-2025
- Business
- Yahoo
Here's Wedgewood Partners' Investment Thesis for Zoetis (ZTS)
Wedgewood Partners, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter, Wedgewood Composite's net return was 7.1% compared to the Standard & Poor's 10.9%, the Russell 1000 Growth Index's 17.8%, and the Russell 1000 Value Index's 3.8% return for the same period. In addition, you can check the fund's best 5 holdings to know its best picks in 2025. In its second quarter 2025 investor letter, Wedgewood Partners highlighted stocks such as Zoetis Inc. (NYSE:ZTS). Zoetis Inc. (NYSE: ZTS) is involved in the research, development, manufacturing, and sale of animal health medications, vaccines, and diagnostic products and services. The one-month return of Zoetis Inc. (NYSE:ZTS) was -5.55%, and its shares lost 17.79% of their value over the last 52 weeks. On July 18, 2025, Zoetis Inc. (NYSE:ZTS) stock closed at $148.60 per share, with a market capitalization of $66.158 billion. Wedgewood Partners stated the following regarding Zoetis Inc. (NYSE:ZTS) in its second quarter 2025 investor letter: "We recently initiated a position in Zoetis Inc. (NYSE:ZTS), the global leader in animal healthcare. The Company provides a range of products from medicines and vaccines to diagnostic testing, plus a variety of related products and services for pets and livestock in over 100 countries. In the U.S., where the Company generates roughly 55% of its revenue, its business skews heavily toward pets. In the rest of the world, the Company's business skews more heavily toward livestock, particularly in developing markets. Globally, the split between animal types falls roughly 70% pet and 30% livestock. A veterinarian administering a vaccine to a herd of cattle in a farm. Zoetis Inc. (NYSE:ZTS) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 74 hedge fund portfolios held Zoetis Inc. (NYSE:ZTS) at the end of the first quarter, compared to 76 in the previous quarter. In the first quarter of 2025, Zoetis Inc. (NYSE:ZTS) posted $2.2 billion in revenue, growing 1% on a reported basis and 9% on an organic operational basis. While we acknowledge the potential of ZTS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Zoetis Inc. (NYSE:ZTS) and shared the list of best dividend stocks in the pharma sector. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20-07-2025
- Business
- Yahoo
Argus Trims Zoetis (ZTS) Price Target to $190, Keeps Constructive View
Zoetis Inc. (NYSE:ZTS) is one of the high-margin pharma stocks to buy now. Argus has trimmed its price target on Zoetis Inc. (NYSE: ZTS) to $190 from $200, maintaining a cautious but constructive view on the animal health giant. While the firm did not change its overall outlook, the revised target reflects a more tempered near-term assessment of valuation and broader market conditions. A veterinarian administering a vaccine to a herd of cattle in a farm. Zoetis, a global leader in veterinary pharmaceuticals and diagnostics, has faced mixed investor sentiment in recent months. Although the company continues to deliver steady growth through its companion animal segment and expanding international footprint, pockets of weakness in livestock-related markets and currency headwinds have pressured earnings expectations. Argus' adjustment comes as analysts across the Street maintain generally favorable views on Zoetis. The stock holds an average rating of Overweight, underscoring confidence in its long-term positioning. Investors are watching closely for updates on pipeline innovation and regulatory approvals, which could help reignite momentum. Despite the reduced price target, Argus emphasized that Zoetis remains well capitalized and strategically focused, with an attractive portfolio that spans vaccines, parasiticides, and diagnostics. The firm sees upside potential as underlying demand trends in pet care normalize and input cost pressures begin to ease. Zoetis shares have been relatively stable year to date, reflecting the broader defensiveness of the animal health sector. While we acknowledge the potential of ZTS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Best Industrial Automation Stocks to Buy for the Next Decade Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
18-07-2025
- Business
- Yahoo
Argus Trims Zoetis (ZTS) Price Target to $190, Keeps Constructive View
Zoetis Inc. (NYSE:ZTS) is one of the high-margin pharma stocks to buy now. Argus has trimmed its price target on Zoetis Inc. (NYSE: ZTS) to $190 from $200, maintaining a cautious but constructive view on the animal health giant. While the firm did not change its overall outlook, the revised target reflects a more tempered near-term assessment of valuation and broader market conditions. A veterinarian administering a vaccine to a herd of cattle in a farm. Zoetis, a global leader in veterinary pharmaceuticals and diagnostics, has faced mixed investor sentiment in recent months. Although the company continues to deliver steady growth through its companion animal segment and expanding international footprint, pockets of weakness in livestock-related markets and currency headwinds have pressured earnings expectations. Argus' adjustment comes as analysts across the Street maintain generally favorable views on Zoetis. The stock holds an average rating of Overweight, underscoring confidence in its long-term positioning. Investors are watching closely for updates on pipeline innovation and regulatory approvals, which could help reignite momentum. Despite the reduced price target, Argus emphasized that Zoetis remains well capitalized and strategically focused, with an attractive portfolio that spans vaccines, parasiticides, and diagnostics. The firm sees upside potential as underlying demand trends in pet care normalize and input cost pressures begin to ease. Zoetis shares have been relatively stable year to date, reflecting the broader defensiveness of the animal health sector. While we acknowledge the potential of ZTS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Best Industrial Automation Stocks to Buy for the Next Decade Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
17-07-2025
- Business
- Yahoo
Veterinary Active Pharmaceutical Ingredients (API) Market Research Report 2025-2034
Growth is driven by rising pet ownership, heightened focus on animal health, and technological advancements in veterinary care. The market is fueled by increased demand for veterinary medications addressing zoonotic diseases and advanced treatment options. Segmented by API type, anti-parasitics lead with significant growth, complemented by chemical-based APIs which dominate due to their cost-efficiency and therapeutic versatility. Companion animal care is thriving, projected to reach USD 10.7 billion by 2034. Regional analysis highlights North America as a key player, propelled by robust pet ownership and strong healthcare infrastructure. Major companies like AMGIS Lifescience, Boehringer Ingelheim, and Vetpharma drive innovation and expansion. Veterinary Active Pharmaceutical Ingredients (API) Market Dublin, July 08, 2025 (GLOBE NEWSWIRE) -- The "Veterinary Active Pharmaceutical Ingredients (API) Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" has been added to Global Veterinary Active Pharmaceutical Ingredients (API) Market was valued at USD 7.9 billion in 2024 and is estimated to grow at a CAGR of 7.4% to reach USD 16 billion by 2034 This steady growth is largely fueled by increasing pet ownership, rising awareness about animal health, and advancements in veterinary technologies. Consumers are becoming more inclined to treat animals with the same level of healthcare they expect for themselves, which has directly impacted the demand for quality veterinary medications. The growing prevalence of zoonotic diseases has also intensified the urgency for reliable treatments, making veterinary APIs more crucial than ever in the development of safe and effective drugs. Veterinary APIs are core ingredients used to formulate medicines that treat, manage, or prevent diseases in animals. These ingredients are essential for both livestock and companion animals, serving a wide range of therapeutic applications. With the increase in global livestock production and pet adoption, there is a consistent need for high-quality APIs that meet regulatory benchmarks such as Good Manufacturing Practices (GMP). APIs are cost-effective due to their compatibility with bulk production, ensuring price efficiency without compromising quality. They also allow pharmaceutical manufacturers to tailor drugs for specific species and dosage forms, including oral, injectable, and feed-based solutions. The flexibility, affordability, and high consistency of APIs make them integral to producing effective veterinary market is segmented by API type into anti-parasitics, anti-infectives, vaccines, biologics, hormones, anti-inflammatories, and other APIs. Among these, anti-parasitics dominated the market with a revenue of USD 2 billion in 2024 and are forecasted to reach USD 4.2 billion by 2034, recording a CAGR of 7.9%. The increasing incidence of parasitic diseases in animals, such as heartworms, fleas, and gastrointestinal infections, is driving the demand for targeted anti-parasitic treatments, which in turn pushes the need for robust and quality APIs in this on synthesis type, the market is categorized into chemical-based APIs, biological APIs, and highly potent APIs (HPAPIs). Chemical-based APIs held the largest share of 58.2% in 2024 due to their cost-efficiency, long shelf life, and ease of mass production. These APIs are widely used in treating a range of conditions like infections and inflammation and serve as the foundational building blocks for many veterinary drugs. Their pharmacological properties make them suitable for combination with other ingredients, enhancing their therapeutic efficacy. Continuous improvements in chemical synthesis technologies are also supporting the increased adoption of these APIs across various veterinary terms of animal type, the market is segmented into livestock animals and companion animals. The companion animals segment is projected to grow at a CAGR of 7.6%, reaching USD 10.7 billion by 2034. This growth is attributed to the increasing trend of pet humanization and the willingness of pet owners to invest in preventive and therapeutic healthcare. Demand for advanced veterinary pharmaceuticals such as biologics, hormones, and anti-inflammatory drugs continues to rise as pet care becomes more specialized and market is further divided by service type into in-house manufacturing and contract outsourcing. In-house manufacturing held the largest market share at 55.3% in 2024 and is projected to reach USD 8.7 billion by 2034. This segment benefits from advantages like enhanced quality assurance, lower production costs, and faster time-to-market for drug development. Companies with in-house API production capabilities are better positioned to manage inventory and adjust to market demands quickly, giving them a competitive edge in the fast-evolving veterinary pharmaceutical North America accounted for the highest revenue of USD 3.1 billion in 2024 and is expected to climb to USD 6 billion by 2034, growing at a CAGR of 7.1%. The region's leadership is reinforced by widespread pet ownership, high awareness of animal health issues, and a strong veterinary healthcare infrastructure. The demand for premium-quality APIs continues to increase as more consumers seek advanced treatments for both pets and livestock, supporting North America's dominant position in the global players actively contributing to the market landscape include AMGIS Lifescience, Abino Pharma, BOC Sciences, Hikal, Huvepharma (Olon), Boehringer Ingelheim, Indukern Group, NGL Fine-Chem, Menadiona, Ofichem Group, Qilu Pharmaceutical, Sequent Scientific, Procyon Life Sciences, SUANFARMA, Vetpharma, and Veyx-Pharma. These companies are focused on strengthening their manufacturing capabilities, expanding their product portfolios, and meeting rising global demand for veterinary APIs. Key Attributes: Report Attribute Details No. of Pages 160 Forecast Period 2024 - 2034 Estimated Market Value (USD) in 2024 $7.9 Billion Forecasted Market Value (USD) by 2034 $16 Billion Compound Annual Growth Rate 7.4% Regions Covered Global Comprehensive Market Analysis and Forecast Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape Competitive landscape with Porter's Five Forces and PESTEL analysis Market size, segmentation, and regional forecasts In-depth company profiles, business strategies, financial insights, and SWOT analysis Drivers Rising pet ownership rate Growing initiative and awareness for animal health Growing technological advancements in drug formulations Rising incidence of zoonotic disease Expanding outsourcing services Challenges Stringent regulatory approval High R&D cost Company Profiles Abino Pharma AMGIS Lifescience BOC Sciences. Boehringer Ingelheim Hikal Huvepharma Indukern Group Menadiona NGL Fine-Chem Ofichem Group Procyon Life Sciences Qilu Pharmaceutical Sequent Scientific SUANFARMA Vetpharma Veyx-Pharma For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Veterinary Active Pharmaceutical Ingredients (API) Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Forbes
09-07-2025
- Health
- Forbes
Joint Blood Drive Highlights Need For Pets And People To Donate Blood
One blood donation from a cat or dog can save the lives of up to three other pets. Courtesy of BluePearl Pet Blood Bank An innovative blood drive aims to increase the flow of blood donations by both people and pets. On July 10, employees of Mars Veterinary Health can visit the Mars Petcare headquarters in Franklin, Tennessee, to donate blood with the American Red Cross of Tennessee and also have their dogs screened as potential blood donors through the BluePearl Pet Blood Bank. (BluePearl Pet Hospital is a specialty and emergency arm of Mars Veterinary Health). While many Americans are aware of the need for human blood donors, fewer are aware that animal hospitals need dogs and cats to donate blood to help save the lives of other pets, according to Lenore Bacek, DVM, MS, DACVECC, vice president of clinical affairs at BluePearl Pet Hospital. 'There's definitely a lack of awareness that our pets have the same needs,' she said. 'They need blood transfusions for all sorts of medical conditions and emergencies, just like people do.' Around 950 dogs and cats currently participate in the pet blood bank program. While most domestic cats have type A blood, exotic breeds often have type B, which is extremely sought after because it's so rare, according to Dr. Bacek. 'When we find a type B donor, we are very excited to have them in the program,' she said. One blood donation from a cat or dog can save the lives up to three other pets, and BluePearl Pet Blood Bank sends a notification to pet parents of donors whenever their blood is used to help another pet. Cats and dogs who donate blood receive perks like free exams and annual bloodwork. getty In addition to the reward of saving the life of another animal, feline and canine blood donors receive a free checkup before every donation and free annual bloodwork. 'I think that is a tremendous financial savings for them,' Dr. Bacek said. 'And we are working with VCA and Banfield, our two sister business units in North America, and they've offered up some discount visits.' Requirements For Dogs And Cats To Donate Blood To Pet Blood Bank The BluePearl Pet Blood Bank is completely voluntary, though the hope is enrolled dogs and cats will donate blood about every 12 weeks, or around four times a year, according to Dr. Bacek. To qualify for the program, dogs must weigh at least 50 pounds and be 1-8 years old. Cats must also fall into that age range and weigh at least 10 pounds. Both species must be considered healthy, be up to date on certain vaccines like rabies and distemper, and take year-round flea, tick and heartworm preventive medication. Dogs and cats cannot be fed a raw diet out of concerns of salmonella transmission; raw poultry diets can also put cats at risk of contracting bird flu). They also can't be taking certain medications or have received a blood transfusion to quality as donors. While most cats are sedated to donate blood, many dogs simply lie still while donating, Dr. Bacek noted. 'It's nice when they're friendly, calm and have a good disposition,' she said. 'We can certainly sedate them, but some of the dogs don't need sedation.' Some dogs don't require sedation while donating blood, which takes about 10 minutes. Courtesy of BluePearl Pet Blood Bank The Blood Donation Process For Dogs and Cats The blood donation process for dogs and cats is 'very, very safe' and only lasts about 10 minutes, according to Dr. Bacek. Afterward, they are typically spoiled with treats and love from the veterinary team, as well as toys and bandanas that read 'I'm a Hero.' Some repeat canine donors are excited when they arrive because they've enjoyed past donation experiences so much. 'It's very quick and we try to make it a very calming, peaceful process,' she said. It can also be a rewarding process. For instance, at a pet blood donor appreciation event in Tampa, Florida, Dr. Bacek and other attendees were touched when a golden retriever who received a blood donation met the blood donor – a Labrador retriever – who saved his life. A Labrador retriever relaxes alongside the golden retriever saved by his blood donation at a ... More BluePearl Pet Blood Bank donor appreciation event in Tampa, Florida. Courtesy of BluePearl Pet Blood Bank So knowing a beloved dog or cat saved another beloved pet through blood donation is often the greatest benefit of participation. 'There is a component that's just very emotional,' she said. 'It's really special to know that your pet actually helped save another pet.' In fact, Dr. Bacek and her husband are enrolling their two cats, Bert and Ernie, in the BluePearl Pet Blood Bank program in hopes of saving the lives of other cats. She hopes tomorrow's joint blood drive inspires other pet parents to do the same. Dr. Lenore Bacek is enrolling her cats, Bert and Ernie, as donors in the BluePearl Pet Blood Bank ... More program. Courtesy of Dr. Lenore Bacek 'We just want people to understand that it's not scary,' she said. 'It's very, very vital for our hospitals to have these products.'
